Reported 29 days ago
Pfizer Inc. reported a third-quarter adjusted EPS of $1.06, a significant improvement from a loss of 17 cents last year, accompanied by sales of $17.70 billion, marking a 31% year-over-year increase. The growth was mainly attributed to the surge in demand for Paxlovid amid a global COVID-19 wave, contributing $2.7 billion in revenues. The company revised its 2024 revenue forecast to $61-$64 billion, expecting around $10 billion from COVID-related products, while also anticipating operational revenue growth of 9% to 11% compared to 2023.
Source: YAHOO